Zeng Yanli, Zhang Yan, Lin Yiqiang, Wang Xuelian, Chen Qinggui, Huang Qinghe, Wang JiaJia, Jiang Longcan, Xiao Yun
Center of Clinical Laboratory, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, 361004, China.
Department of Obstetrics and Gynecology, Zhongshan Hospital of Xiamen University, Xiamen, 361004, China.
Clin Exp Med. 2021 Nov;21(4):611-619. doi: 10.1007/s10238-021-00707-x. Epub 2021 Apr 12.
The aim of our study was to assess the regulatory response of the chemokine CXCL13 in the serum of systemic lupus erythematosus (SLE) patients with disease activity and to evaluate its influence on the inflammatory process in SLE. Serum samples from 97 SLE patients, 49 non-SLE patients (23 patients with other autoimmune diseases and 26 patients with rheumatoid arthritis) and 50 healthy controls were analyzed for the concentration of CXCL13 using ELISA. The results indicated that the serum levels of CXCL13 were significantly higher in SLE patients than in non-SLE patients and healthy controls (p < 0.001). Moreover, the level of CXCL13 decreased as the level of anti-dsDNA IgG decreased after treatment between the anti-dsDNA-positive SLE patients and the anti-dsDNA-negative SLE patients. In addition, serum CXCL13 levels were correlated with SLEDAI in different activities of SLE, renal involvement and active LN. Furthermore, the level of CXCL13 was positively related to the SLEDAI, level of anti-dsDNA IgG, level of ESR and RAI of high-avidity IgG ANAs (HA IgG ANAs). Additionally, statically analysis revealed that CXCL13 would be a best diagnostic value for determining the disease activity of SLE due to its moderate sensitivity (93.5%), specificity (95%), PPV (98.6%), NPV (79.2%) and OR(95%CI,250(30.303-1000)), at a cut-off level of 15.27 pg/mL. First, we indicated that CXCL13 was elevated in SLE patients regardless of the presence or absence of anti-dsDNA IgG ANAs. Furthermore, HA IgG ANAs might affect the circulation of CXCL13. Therefore, the chemokine CXCL13 might be a risk factor influencing the inflammatory process in SLE.
我们研究的目的是评估趋化因子CXCL13在有疾病活动的系统性红斑狼疮（SLE）患者血清中的调节反应，并评估其对SLE炎症过程的影响。采用酶联免疫吸附测定法（ELISA）分析了97例SLE患者、49例非SLE患者（23例患有其他自身免疫性疾病，26例患有类风湿性关节炎）和50例健康对照者的血清样本中CXCL13的浓度。结果表明，SLE患者血清中CXCL13水平显著高于非SLE患者和健康对照者（p＜0.001）。此外，抗双链DNA（anti-dsDNA）阳性的SLE患者和抗dsDNA阴性的SLE患者治疗后，随着抗dsDNA IgG水平下降，CXCL13水平也降低。另外，血清CXCL13水平与SLE不同活动度、肾脏受累及活动性狼疮性肾炎（LN）中的SLE疾病活动指数（SLEDAI）相关。此外，CXCL13水平与SLEDAI、抗dsDNA IgG水平、红细胞沉降率（ESR）水平及高亲和力IgG抗核抗体（HA IgG ANAs）的类风湿因子（RAI）呈正相关。此外，统计学分析显示，CXCL13在截断水平为15.27 pg/mL时，因其具有中等敏感性（93.5%）、特异性（95%）、阳性预测值（PPV，98.6%）、阴性预测值（NPV，79.2%）和比值比（OR，95%可信区间，250（30.303 - 1000）），对判断SLE疾病活动具有最佳诊断价值。首先，我们指出无论有无抗dsDNA IgG抗核抗体，SLE患者体内CXCL13均升高。此外，HA IgG抗核抗体可能影响CXCL13的循环。因此，趋化因子CXCL13可能是影响SLE炎症过程的一个危险因素。
